scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
51 hedge funds and large institutions have $129M invested in scPharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
55% more funds holding
Funds holding: 33 → 51 (+18)
40% more capital invested
Capital invested by funds: $92.4M → $129M (+$36.7M)
5.93% more ownership
Funds ownership: 59.53% → 65.46% (+5.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12.2M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.57M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
+$5.08M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.47M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$346K |
| 2 |
Millennium Management
New York
|
-$259K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$220K |
| 4 |
MC
Matisse Capital
Portland,
Oregon
|
-$87.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$87K |
SCPH Hedge Fund Activity: Q2 2020 in Review
51 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2020, worth a combined $129M — up 40% from $92.4M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new SCPH positions and 5 closed out — a net gain of 18 holders — while 20 added to existing stakes and 6 trimmed.
The largest buyer was OrbiMed, adding an estimated $12.2M. The largest seller was JP Morgan Chase, cutting an estimated $346K.
- 51 institutional investors held scPharmaceuticals (SCPH) as of Q2 2020, up from 33 in Q1 2020.
- Funds reported $129M of scPharmaceuticals stock for Q2 2020, up 40% quarter-over-quarter.
- 23 funds opened new scPharmaceuticals positions in Q2 2020 and 5 closed out, a net change of +18 holders.
- The largest scPharmaceuticals buyer in Q2 2020 was OrbiMed, an estimated $12.2M added.
- The largest scPharmaceuticals seller in Q2 2020 was JP Morgan Chase, an estimated $346K sold.
Based on aggregated 13F filings for Q2 2020.